| Subcribe via RSS

Phase III Data Show Vanda Pharmaceuticals’ Tasimelteon (VEC-162) Significantly Improves Sleep In Patients With Chronic Insomnia

June 27th, 2008 Posted in Medical Information
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) (Vanda) announced positive top-line results from a Phase III trial showing that its investigational drug candidate, tasimelteon (VEC-162), a novel melatonin agonist, met the primary endpoint of the trial and significantly improved sleep in adult patients with chronic insomnia.
Tags:

Similar Posts


This entry was posted on Friday, June 27th, 2008 at 3:00 am and is filed under Medical Information. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

Leave a Reply